contamination with own skin bacteria S. aureus carriage
Conditions
Interventions
Patients will be randomized to a search and destroy (SD) strategy: a quick and
short, systemic antibiotic treatment (nasal
mupirocin ointment, oropharyngeal chlorhexidine rinse, chlorhexidine body wa
intestinal failure
Sponsors
Radboud Universitair Medisch Centrum
Eligibility
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: - Patient is fully able to understand the nature of the proposed intervention. - Patient is diagnosed with intestinal failure and on HPN and/or fluid replacement - Written informed consent by the patient before entering the trial. - Age * 18 years. - Estimated life expectancy * 1 year. - Patient colonized with S. aureus.
Exclusion criteria
Exclusion criteria: - Cannot be expected to comply with the trial plan (substance abuse, mental condition). - Pregnant or breastfeeding women. - Continuous exposure to MRSA (e.g. pig farmer). - Allergy for chlorhexidine and betadine. - No options for oral and/or topical antibiotics due to allergies and/or resistance. - Active S. aureus infection. - Currently on treatment with antibiotics active against S. aureus. - Decolonization (including mupriocin) treatment in the previous two months. - The presence of an unremovable nasal foreign body. - AST and ALT levels more than five times the upper limit of normal or liver failure.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome: proportion of patients eradicated for S. aureus (nose, throat, rectum, exit-site catheter) during one year. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes: long-term antimicrobial resistance, adverse events, patient compliance, incidence of (S. aureus) infections, catheter removals, mortality rates, S. aureus transmission routes, quality of life and costs. | — |
Countries
Denmark, Netherlands
Outcome results
None listed